Skip to content

Effect of Early Enteral Nutrition After Gastric Surgery on Patient Prognosis

Effect of Early Enteral Nutrition After Gastric Surgery on Patient Prognosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117803
Enrollment
Unknown
Registered
2026-01-29
Start date
2026-01-31
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer and gastric surgery related diseases

Interventions

Experimental Group:Postoperative administration of amino acid-based enteral nutrition (Ailento), gradually increasing energy to the target level.
Control Group:Postoperative conventional treatment without Ailento.

Sponsors

Shanghai Tenth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-80 years. 2. Patients who underwent gastric-related surgery within 48 hours, such as subtotal gastrectomy, total gastrectomy, radical gastrectomy for gastric cancer, or gastric bypass. 3. Patients with no other organic or mental diseases. 4. Patients or their families are informed and have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. History of allergy to ingredients in the enteral nutrition. 2. Severe dysfunction of heart, liver, or kidney; severe disturbance of the internal environment. 3. Severe diabetes or heavy use of steroids. 4. Severe gastrointestinal failure, intestinal obstruction, intra-abdominal infection, or other conditions unsuitable for early enteral nutrition support. 5. Pregnant or lactating women. 6. Patients with amino acid metabolism abnormalities. 7. Other patients deemed unsuitable for participation by medical staff.

Design outcomes

Primary

MeasureTime frame
Time to first flatus;Time to first defecation;Time to resumption of oral diet;Postoperative length of hospital stay;Endotoxin;Incidence of adverse events and complications;

Secondary

MeasureTime frame
Serum Prealbumin;Albumin;Hemoglobin;Plasma Citrulline;

Countries

China

Contacts

Public ContactChunqiu Chen

Shanghai Tenth People’s Hospital

chenchunqiu6@126.com+86 1371864838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026